

EVIDENCE OF HIV/HCV COINFECTION AMONG PEOPLE LIVING WITH HIV/AIDS ATTENDING FEDERAL MEDICAL CENTRE, YENAGOA, NIGERIA

Okonko IO & Shaibu N

Virus & Genomics Research Unit, Department of Microbiology, University of Port Harcourt, Port Harcourt, Nigeria.

E-mail address: iheanyi.okonko@uniport.edu.ng; Tel: +2347069697309

ORCID iD: [0000-0002-3053-253X](https://orcid.org/0000-0002-3053-253X)

ABSTRACT

Coinfection of hepatitis C (HCV) may compromise antiretroviral therapy (ART) in Nigeria. In this study, we evaluated the seroprevalence of HIV/HCV coinfection in people living with HIV/AIDS (PLWHA) receiving ART and associated factors. Patients were selected from HIV-1-infected patients enrolled in National HAART Cohort at Federal Medical Centre in Yenagoa, Nigeria. Following the manufacturer's instructions, medical assessments and anti-HCV antibody serology were obtained for analysis with an ELISA kit (Dia. Pro). A total of 4 of 104 PLWHA tested were anti-HCV antibody positive (4.0%). HIV/HCV coinfections were higher in age groups ≥ 41 years (4.4%), males (7.0%), CD4 counts 350-499 cells/ μ l (7.1%) and PVL ≥ 1000 copies/ml (10.0%). CD4 counts and viral load were an indicator for HIV/HCV coinfections. Socio-demographic variables were not associated ($p > 0.05$) with HIV/HCV coinfection in univariate analysis; older PLWHA were more likely to be HCV-positive. Males were more prone to HIV/HCV coinfection than females. HIV status did seem to influence the predisposition to HCV infection, as an increase in susceptibility was observed with HIV-infected patients in Yenagoa, Nigeria. The high prevalence of HIV/HCV coinfection in PLWHA in Yenagoa receiving ART demands routine screening for viral hepatitis coinfection, intensive prevention of childhood HCV transmission, and modification of the management of HIV infection.

Keywords: Antibodies, Coinfection, HCV, HIV, Prevalence, Nigeria

1. INTRODUCTION

Hepatitis C virus (HCV) is a significant cause of chronic hepatitis, liver cirrhosis, liver disease and hepatocellular carcinoma (HCC) worldwide (Cooke et al., 2013; Colpitts et al., 2020; Tsai et al., 2020; Hsu et al., 2022) and a common indication for liver transplantation (Patnaik & Tsai, 2022). Following infection, the majority of individuals will develop chronic hepatitis C that may subsequently lead to liver cirrhosis and cancer (Colpitts et al., 2020). Emerging evidence has indicated an association between HCV and atherosclerotic cardiovascular disease (Lee et al., 2019).

According to WHO (2023c), 290 000 persons died from hepatitis C in 2019, primarily from cirrhosis and hepatocellular carcinoma (primary liver cancer). Globally, it is estimated that 71 million people have chronic HCV infections (Polaris Observatory HCV Collaborators, 2017; Hsu et al., 2022). There is no vaccine to prevent HCV infection (Colpitts et al., 2020; WHO, 2023c); however, the development of safe and highly effective HCV therapy with direct-acting antiviral agents has revolutionized the management of HCV, liver transplant candidates and transplant recipients (Patnaik & Tsai, 2022).

About 38.4 million persons will live with the human immunodeficiency virus (HIV) globally in 2021, while about a quarter of this is in Africa (WHO, 2023a, b). The frequency of HIV is now becoming an epidemic in our world, especially in developing countries such as Nigeria. Usually, HIV infection has a long-term prognosis; some people get AIDS quickly and pass away within a few years if untreated (Okonko et al., 2020a, b). The presence of

HCV further complicates this condition, as results from countries with highly active antiretroviral therapy (HAART) suggest liver diseases associated with HCV play a significant role in deteriorating health and increasing the mortality rate in persons living with HIV (Konopnicki et al., 2005; Okonko et al., 2020a, b, WHO, 2020). Another significant obstacle is coinfection since it slows the progression of the illness to AIDS (Okonko et al., 2020a, b).

Human Immunodeficiency Virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) are the three most common chronic viral infections of public health importance with significant socio-economic impact worldwide (Muriuki et al., 2013; Esan et al., 2014; Lawal et al., 2020). Both HBV and HCV infections cause acute and chronic liver infections with the potential for liver cirrhosis and hepatocellular carcinoma (HCC) (Cooper et al., 2009; Abera et al., 2014; Lawal et al., 2020). Hepatitis C leads to chronic infection in 60.0–80.0% of patients after acute infection (Sadoh et al., 2011; Ejeliogu et al., 2014; Lawal et al., 2020), while perinatal HBV infection is associated with a 90.0% risk of chronicity compared with a risk of less than 5.0% among adults with intact immunity (Paganelli et al., 2012; Lawal et al., 2020).

Globally, over 350 million and 170 million people are chronically infected with HBV and HCV, respectively (Nel et al., 2012; Abera et al., 2014; Lawal et al., 2020). In Africa, about 100 million individuals are estimated to be infected with HBV or HCV (Lemoine et al., 2015; Lawal et al., 2020). Furthermore, 80.0% of liver cirrhosis and HCC cases in Africa are caused by HBV and HCV infections, with HBV being the primary contributor to end-stage liver disease (Lemoine et al., 2015; Lawal et al., 2020).

Although varied, the prevalence of HCV/HIV coinfection is lower than that of HBV/HIV coinfection worldwide. In a large group of children who were perinatally HIV-positive and were part of a long-term follow-up program, the prevalence of HCV infection in the United States was 1.5%, compared to a rate of 9.6% in China (Schuval et al., 2004; Zhou et al., 2010; Lawal et al., 2020). However, several African nations, such as Tanzania, where a prevalence of 13.8% has been recorded, and Ethiopia, where the prevalence of anti-HCV ranged from 0.0% to 22.0%, have seen a higher incidence of this coinfection (Deress et al., 2021). On the other side, Cote d' Ivoire in West Africa recorded a prevalence rate of 0.0% (Telatela et al., 2007; Rouet et al., 2008; Riou et al., 2016; Lawal et al., 2020) and in Ivory Coast and Kenya (Puoti et al., 2008; Rouet et al., 2008). Similarly, studies in Port Harcourt, Nigeria, and East Africa found 0.0% prevalence rates for HIV/HCV coinfection (Chakraborty et al., 2003; Okonko et al., 2014; Lawal et al., 2020; Cookey et al., 2021). Lagos, Nigeria, reported a 0.5% prevalence incidence of HIV/HCV coinfection (Lawal et al., 2020).

Its endemicity has long been validated in Nigeria, but there is less information about its epidemiology (Riou et al., 2016; Abeni et al., 2020; Okonko & Ernest Nwagwu, 2023). There is an established relationship between HIV positivity and the progression of HCV infection; dual positivity with HIV influences the clinical outcome of HCV infection (Villano et al., 1999; Thomas et al., 2000; Sulkowski & Thomas, 2003; Ogbodo et al., 2015; Okonko et al., 2022). The alarming statistics have made it crucial that studies be also done to ascertain the HIV/HCV coinfection prevalence in the country and host factors which may influence the coinfection (Cookey et al., 2021).

We know very little research on HCV, coinfections among HIV-positive individuals, and related risk factors in Bayelsa State, Nigeria. In order to establish a baseline of knowledge,

this study was carried out to ascertain the serological evidence, prevalence, and coinfection rates among HIV-positive individuals in Yenagoa, Nigeria.

2. MATERIAL AND METHODS

2.1. Study Area

The Federal Medical Center in Yenagoa, Bayelsa State, Nigeria, was the site of the study. This hospital is one of the primary treatment centres in Bayelsa State, Southern Nigeria, for people living with HIV and AIDS (PLWHA). Yenagoa is a Local Government area and city of Bayelsa State, Nigeria. It is located in the southern part of the country. The LGA has an area of 706 km² and a population of over 352,285 as of 2006. The Ijaw form the majority of the state. Bayelsa is situated in an area of swamps, mangroves, and tropical rainforests, and it is located in the core of the Niger Delta region. Bayelsa state was formed in 1996 by Rivers State, making it one of the newest in the federation. The state borders River State, of which it was formerly part of and Delta state. The state is the smallest in Nigeria by population as of the 2006 Census and one of the smallest by area. Bayelsa State has a riverine and estuarine setting, with bodies of water within the state preventing the development of significant road infrastructure. Petroleum is the primary sector of the Bayelsa economy.

2.2. Study Design

The current investigation, which aims to ascertain the prevalence of HIV/HCV coinfections among people living with HIV and AIDS (PLWHA) attending Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria, utilized a hospital-based cross-sectional study design. The method for this study consists of informed consent and blood withdrawal by venipuncture. Screening for HIV/HCV coinfections, clinical evaluation and recording of demographic information such as the age of the participants, sex, marital status, educational background, occupation, and use of ART.

2.3. Ethics statement

Administrative approval for this study was obtained from the management of the Federal Medical Centre, Yenagoa, Nigeria. Ethical considerations and approval for the study were obtained from the University of Port Harcourt Research Ethics Committee following the ethics for research involving human subjects. Before samples were obtained and analyzed, all subjects provided their informed consent. General information regarding the nature of the study and its objectives was explained to participants, who were also informed of the right of refusal to participate in the study or to withdraw at any time without jeopardizing their right to access other health services. Identification codes were used instead of names, and the information collected was kept confidential. This study followed the World Medical Association's (WMA) Declaration of Helsinki, which sets forth the standards for medical research involving identified human/animal subjects, human subjects, and animal subjects.

2.4. Study population

Here, 104 PLWHA positively confirmed patients attending the HIV outpatient clinic of Federal Medical Centre, Yenagoa, Nigeria, who willingly gave informed consent and volunteered to have their blood samples examined were recruited into the study. Patients attended the clinic for routine check-ups, collection of medications or other medical complaints. Socio-demographic data of the patients were collected. Necessary demographics (age, sex, marital status, educational background and occupations) and clinical and epidemiological data of each patient were obtained using a well-structured questionnaire. Health personnel conducted the interview and entered the data according to the pre-structured questionnaire. All PLWHA positively confirmed patients were eligible

for the study. HIV-infected patients with duplicate records or missing information about their socio-demographic data were excluded from the study. However, PLWHA, who were accurately recorded in the registration book, was included.

2.5. Sample collection

The method of sample collection employed was the vein puncture technique. A soft tourniquet was fastened to the upper hand of the patient. The punctured site was cleansed with methylated spirit, and the vein was punctured with a 3ml syringe. After sufficient blood collection, the tourniquet is released, and the needle is removed immediately. About 3 ml of venipuncture blood was collected in EDTA BA Vacutainer TM anti-coagulant tubes (BD, Franklin Lakes, USA), labelled with each patient's details. Plasma specimens were separated by centrifugation at 3 000 rpm (revolution per minute) for 5 min. The plasma utilized for the laboratory tests was kept at -20°C.

2.6. Serological analysis of HCV Antibody

Blood samples of HIV-positive patients were taken using the venipuncture technique. In the Virology & Genomics Research Unit, Department of Microbiology, University of Port Harcourt, Nigeria, plasma was examined for anti-HCV antibodies using an enzyme-linked immunosorbent assay using a commercial kit (DIA.PRO Diagnostic Bioprobes, Milano, Italy) (ELISA). Laboratory testing was carried out according to the manufacturer's instructions, and all tests were done utilizing quality controls according to standard operating procedures. A microplate reader for an ELISA was used to read the optical signals produced in the microwells at 450 nm (Model ELx808i, BioTek Instruments, USA). The formula for calculating the cut-off OD_{450nm} (OD of negative control plus 0.350), which we utilized as a threshold for differentiating between reactive and non-reactive blood samples, was provided by the manufacturer of the ELISA kit. In order to determine the following cut-off formulation, the test results were derived using the mean OD_{450nm} value of the negative control (NC) and a mathematical calculation: NC + 0.350 is cut-off (CO). Samples were deemed non-reactive for antibodies specific to the HCV antigens present if their OD_{450nm} was below the cut-off value. Samples were deemed to have antibodies specific to the HCV antigens present if their OD_{450nm} was more significant than the Cut-Off value. According to the manufacturer's instructions, the results were interpreted. The values obtained were used to interpret the results: S/CO 0.9 negative, 0.9-1.1 equivocal, and >1.1 positives. The results were calculated as the ratio of the sample OD_{450nm} and the cut-off value.

2.7. CD4 and Viral Load Analysis

Blood samples were analyzed for CD4+ T cell estimates by flow cytometry and viral load by Abbott Real-Time protocol.

2.8. Data analysis

Data were analyzed using SPSS version 20.0 (SPSS Inc. Chicago, IL, USA). HIV/HCV coinfections among PLWHA were compared to CD4+ T cell count, viral loads, socio-demographic variables and ART using Pearson's chi-square (χ^2) or Fisher's exact test, where appropriate. Statistical significance for all analyses was determined at a 5% significance level.

3. RESULTS

3.1. Study Population Characteristics

Here, we describe the result of the serological analysis of 104 HIV-positive patients attending the antiretroviral clinic at the Federal Medical Centre, Yenagoa. The participants' age, sex, marital status, educational attainment, occupations, CD4 counts, and plasma

viral loads were stratified, and all of the samples underwent serological analysis. Table 1 highlights the characteristics of the study group.

Table 1: Patients Characteristics

Variables	Categories	No. Tested	Percentage (%)
Age groups (Years)	8-20	8	7.7
	21-40	51	49.0
	41 & above	45	43.3
Sex	Females	75	72.1
	Males	29	27.9
Marital Status	Singles	43	41.4
	Married	56	53.9
	Divorced	5	4.8
Educational Background	Primary	17	16.4
	Secondary	43	41.4
	Tertiary	42	40.4
	None	2	1.9
Occupations	Self-Employed	27	26.0
	Unemployed	10	9.6
	Business/Trader	29	28.0
	Students	23	22.1
	Artisans	7	6.7
	Civil Servants	8	7.7
CD4 Counts (Cells/μl)	<200	54	52.0
	200-349	10	9.6
	350-499	14	13.5
	500 & above	26	25.0
Viral Loads (Copies/ml)	<20	53	51.0
	20-999	41	39.4
	1000 & above	10	9.6
Total		104	100.0

3.2. HIV/HCV Coinfection

Overall, HIV/HCV coinfection was determined to be 4.0% (Figure 1).




Figure 1: Overall HIV/HCV coinfection

3.3. Age-specific HIV/HCV coinfection

Higher HIV/HCV coinfection also occurred among age groups ≥ 41 years (4.4%) than 21–40 years (4.0%) and ≤ 20 years with 0.0% (Figure 2). These differences were not statistically associated ($p = 0.83$).




Figure 2: HIV/HCV coinfections with Age

3.4. Sex-specific HIV/HCV coinfection

Higher HIV/HCV coinfection was observed among males (7.0%) than in females (3.0%) (Figure 3). No significant association existed between HIV/HBV coinfection and sex ($p = 0.31$).




Figure 3: HIV/HCV coinfections with Sex

3.5. Marital Status-specific HIV/HCV coinfection

Higher HIV/HCV coinfection occurred among singles (5.0%) than the married (4.0%) and divorced (0.0%) (Figure 4). No significant association existed between HIV/HCV coinfection and marital status ($p = 0.87$).




Figure 4: HIV/HCV coinfections with Marital Status

3.6. Educational Background-specific HIV/HCV coinfection

Higher HIV/HCV coinfection was observed among those with tertiary educational backgrounds (5.0%) than those with secondary education (4.6%) and primary education with 0.0% (Figure 5). No significant association existed between HIV/HCV coinfection and educational background ($p = 0.82$).




Figure 5: HIV/HCV coinfections with Educational Background

3.7. Occupation-specific HIV/HCV coinfection

Higher HIV/HBV coinfection occurred among self-employed (7.4%) than business/traders (7.0%) and other occupations with 0.0% (Figure 6). No significant association existed between HIV/HCV coinfection and occupations ($p = 0.61$).




Figure 6: HIV/HCV coinfections with Occupation

3.8. CD4 Counts-Related Specific HIV/HCV coinfection

In terms of CD4 counts, higher HIV/HCV coinfection (7.1%) was observed for participants with CD4 counts 350-499 cells/ μ l than <200 cells/ μ l (5.6%) and \geq 500 cells/ μ l (3.8%) while 200-349 cells/ μ l had the least, 0.0% (Figure 7). No significant association existed between HIV/HCV coinfection and CD4 counts ($p = 0.85$).




Figure 7: HIV/HCV coinfections with CD4 Counts

3.9. Viral Loads-Related Specific HIV/HCV coinfection

In terms of viral loads, higher HIV/HCV (10.0%) occurred among participants that had \geq 1000 copies/ml than those with <20 copies/ml (3.8%) and 20-999 copies/ml with 2.4% (Figure 8). No significant association existed between HIV/HCV coinfection and viral loads ($p = 0.54$).




Figure 8: HIV/HCV coinfections with Viral Loads

4. DISCUSSION

As much as 2%–3% of the world's population may be infected with the hepatitis C virus (HCV), making it a significant worldwide health concern (Alter et al., 2007; Mohd Hanafiah et al., 2013; Benova et al., 2014). Because it persists in about 85.0% of infected people, HCV infection is clinically significant because it presents a serious risk of chronic liver damage (Omolade & Adeyemi, 2018; Okonko & Ernest Nwagwu, 2023). Antiretroviral therapy (ART) in Nigeria could be compromised by coinfection with the hepatitis C virus (HCV). To establish a baseline for future research, this study examined the serological prevalence of HCV and coinfections among people with HIV/AIDS (PLWHA) in Yenagoa, Nigeria. HCV had a 4.0% coinfection prevalence rate among the 104 PLWHA. This result implies little evidence of HCV and HIV coinfection among research participants.

The 4.0% coinfection rate with HCV contradicts the 15.0% and 23.5% reported by Ogbodo et al. (2015) and Ogwu-Richard et al. (2015) in Nigeria. It also contradicts the findings of Okonko et al. (2014) and Cookey et al. (2021), who determined that 0.0% of Port Harcourt, Nigeria, residents have HCV antibodies. Elsewhere, it is comparable to Tsai et al. (2015), who reported a 4.7% HIV/HCV coinfection in Southern Taiwan and Ionita et al. (2017), who reported 4.4% in Nepal. Moreover, it is comparable to China's 4.9% (Zhou et al., 2010).

Contrarily, the rate of HIV/HCV coinfection in this study is higher than that of studies done in Ethiopia, which revealed a 1.3% rate (Balew et al., 2014). This 4.0% is also higher than the 0.5% for HIV/HCV coinfection among HIV-infected and HIV-naïve children in Lagos (Lawal et al., 2020), the 1.7% in Northcentral, Nigeria (Durowaye et al., 2014), the 1.5% in the USA (Schuval et al., 2004), 1.0% was recorded by Aaron et al. (2021) in Port Harcourt, Nigeria, the 0.16% prevalence in the southeast of Nigeria (Ikeako et al. (2014), 0.5% in Anyigba (Omatola et al., 2019), 0.7% in the southeast (Diwe et al., 2013), 0.8% in Abuja (Agboghoroma & Ukaire, 2020), 0.8% in Osogbo (Oluremi et al. (2021), 0.9% reported by Onyekwere and Hameed (2015) and 2.0% in Ethiopia (Deress et al., 2021).

The prevalence of HIV/HCV coinfection in this study was 4.0%, lower than the 5.8%, 5.8%, and 6.02% found in Southeast and South-South, Nigeria (Ikpeme, 2013; Nwolisa et al., 2013). This 4.0% is also lower than the 5.5% in Kumasi, Ghana (Boateng et al., 2019), 7.0% and 7.5% in Lagos, Nigeria (Lawal et al., 2020), 8.1% in Ondo State, Nigeria (Ogundele et al., 2017), 9.6% in China (Zhou et al., 2010) and 22.5% in Port Harcourt, Nigeria (Okonko et al., 2022). It is also lower than the 5.8% and 10.8% recorded by Benova et al. (2014), the 5.2% and 5.0% in Benin and Jos, respectively (Sadoh et al., 2011; Ejeliogu et al., 2014). Compared to China's 62.4% and 50.2% claims, the 4.0% is significantly lower (Chen et al., 2013). The mixed population could explain these results that some authors studied in Nigeria, where teenagers were more likely to have HIV/HCV coinfections (Sadoh et al., 2011). The people analyzed were all HAART-experienced, which may also explain the low prevalence of coinfection reported in the cohort in contrast to Ejeliogu et al. (2014); all their study participants were HAART naïve.

According to prevalence reports from Nigeria and other countries (Oni & Harrison, 1996; Ogboghodo et al., 2009; Khaderi et al., 2014; Eke et al., 2015; Fox et al., 2015; O'Leary et al., 2017), the prevalence rate of 4.0% for HIV/HCV in the current study is not comparable to prevalence reports from those countries. This study further supports the low frequency of HCV in children and the general population. In contrast to the prevalence in this study, greater prevalence rates of 10.0% in Northern Nigeria and 30.30% in Plateau State, Nigeria, were reported by Isa et al. (2015) and Odjimogho et al. (2018),

respectively. This observation is also related to the variation in the distribution of HCV infection and the fact that the sample size in the prior study was slightly similar. Similar transmission routes for viruses in the study participants and the restricted availability of health information regarding the spread and control of HCV infection in the study region could be potential causes of the disparities in this investigation.

The coinfection rate of HIV/HCV in this study was significantly higher among older participants, which differs from a study reported by Ogbodo et al. (2015) in Ughelli, Delta State, Nigeria and Abeni et al. (2020) in Port Harcourt, Nigeria. However, it corroborates our recent study in Port Harcourt, Nigeria (Okonko et al., 2022) and Ogbakiri, Emohua LGA, Rivers State, Nigeria (Okonko & Ernest Nwagwu, 2023). It also supports Tessema et al.'s (2010) study in Plateau State, Nigeria (Odjimogho et al., 2018). It also supported the observation made in a study in China (Chen et al., 2013) and Taiwan (Tsai et al., 2021). This study indicates that the elderly are more susceptible to HCV/HIV coinfection than other age groups. This result might be the weakened immune system of the elderly and end-stage liver disease complications. Therefore, it can be assumed that age is a very significant independent predictor of HIV/HV coinfection.

The current study recorded a higher prevalence among males (7.0%) than females (3.0%). Contributory factors may be attributed to socio-economical, hormonal, or immunological factors. Sexual activities and societal freedom can also influence the prevalence rate of HIV/HCV coinfection in males. This observation is similar to Gupta et al. (2018), who recorded that males were found to be HCV positive in greater percentage than females, which may be assumed that in India, males look for healthcare services earlier than females. Rao et al. (2015) and Odjimogho et al. (2018) have reported findings contrary to this observation. This high infection rate in males than in females may be due to the spontaneous clearance of acute infection in females. The reason for this clearance has been attributed occurrence of certain genetic factors. Other researchers from other parts of Nigeria have verified this demographic tendency (Egah et al., 2004; Buseri et al., 2009; Udeze et al., 2009; Okonko et al., 2012; Kassim et al., 2012; Okocha et al., 2015; Ionita et al., 2017; Okoroiwu et al., 2018; Abeni et al., 2020) and a study in China (Chen et al., 2013). However, this observation differs from other studies in Nigeria (Lesi et al., 2007; Udeze et al., 2011; Balogun et al., 2012; Jemilohun et al., 2014; Ogbodo et al., 2015; Okonko et al., 2022; Okonko & Ernest Nwagwu, 2023).

The current study showed that HCV prevalence was highest in singles. This observation is discordant with the reports of Umumararungu et al. (2017), who documented a higher prevalence among married and divorced/widowed people than singles. Our observation supports previous studies in Nigeria, which observed higher rates among singles than married (Abeni et al., 2020; Okonko et al., 2022; Okonko & Ernest Nwagwu, 2023). This high prevalence may imply that transmission of HEV via sex is essential. To break the cycle of HCV transmission, it is highly recommended that screening among sexually active individuals be performed.

Furthermore, a higher HIV/HCV coinfection occurred among those with a tertiary educational background than those with secondary and primary education. This observation supported a prior study in Nigeria (Okonko et al., 2022) and disputed the findings of other authors (Onyekwere et al., 2016; Ionita et al., 2017; Okonko & Ernest Nwagwu, 2023).

Concerning occupation, the positivity of HCV/HIV occurred more in self-employed (7.4%) and business/traders (7.0%) than in other occupational groups (0.0%). It can be assumed

that these individuals reside in rural areas where there is a lack of public awareness/enlightenment about HIV/HCV coinfection. Logical reasoning could also be that, although uncommon, these individuals can become infected when healthcare professionals do not follow the proper steps to prevent the spread of blood-borne infections, share personal items, and have sex with an infected person. It can be assumed that most of these fore mentioned individuals might be traditional practitioners. Unsafe injections by traditional practitioners could be that these individuals are observed to have little or low educational attainment resulting in ignorance and naiveness.

Regarding CD4 counts, study participants who had HIV/HCV coinfection in this study have higher CD4 count (350-499 cells/ μ l), which is incomparable with the studies conducted in South Africa and Southern Nigeria (Lodenyo et al., 2000; Olufemi et al., 2009). These contentious findings may result from the study's viral hepatitis or may be related to individual participant immune status disparities. In individuals with HIV/HCV coinfections, there may be high HIV and HCV viral replication that may further impair the patient's immune system.

Regarding viral loads, higher HIV/HCV occurred among participants with viral load \geq 1000 copies/ml than those with <20 copies/ml and 20-999 copies/ml. Contrary to our expectations, immunity was boosted, as indicated by increased CD4+ T-cell count in the HIV/HCV group compared to that of the HIV mono-infection group. Even the rate was twice as high as the HIV/HCV group. However, a similar viral load was recorded in the HIV/HCV and HIV mono-infection, respectively (Boateng et al., 2019). One school of thought could be that HCV inhibits or reduces CD4+ T-cells clearance by HIV (Boateng et al., 2019). Another line of reasoning is that HCV, as previously documented, promoted CD4+ T-cell activation (BenMarzouk-Hidalgo et al., 2016; Boateng et al., 2019).

Many demographic, virological, clinical, and lifestyle factors are linked to the natural course of HCV infection. These factors differ significantly across populations, locations, and time (WHO, 2017; Yu et al., 2021).

In this study, none of the socio-demographic characteristics of these participants was significantly associated ($p > 0.05$) with HIV/HCV coinfections.

5. CONCLUSION

In Yenagoa, Nigeria, HCV coinfections among people with HIV and AIDS (PLWHA) have been further validated by the current investigation. The total prevalence of HIV/HCV coinfections in this study was 4.0%. Viral load and CD4 counts served as indicators for HIV/HCV coinfections. Whereas their female counterparts showed a larger propensity to HIV infection alone, males had a higher propensity for HIV/HCV coinfection. Notwithstanding the low rates of HCV coinfection seen in this study, routine testing for HCV indicators should be done to lower morbidity and death in this group. More research is advised to comprehend ART's effect on HCV in PLWHA fully.

Compliance with ethical standards

Acknowledgements

The authors would like to acknowledge the support obtained from the management and staff of Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria, Nigeria, during the enrollment and collection of samples used in this study. The authors are grateful to the participants for their willingness to be part of the study and to Dr T. I. Cookey for the statistical analysis.

Disclosure of conflict of interest

The authors claim that there are no conflicting interests.

Statement of ethical approval

The Federal Medical Centre in Yenagoa, Nigeria, offered their administrative authorization for this study. All authors affirm that the University of Port Harcourt Research Ethics committee has reviewed and approved all experiments. As a result, the study is conducted in accordance with the ethical guidelines outlined in the 1964 Declaration of Helsinki.

Statement of informed consent

"All authors declare that all individuals participating in the study gave their free and informed permission."

REFERENCES

- Aaron, U. U., Okonko, I. O. & Frank-Peterside, N. (2021). The Prevalence of Hepatitis E, Hepatitis C and Hepatitis B Surface Antigenemia in HAART Experienced People Living with Human Immunodeficiency Virus (HIV) in Rivers State, Nigeria. *Journal of Biomedical Sciences*, 10(S4):001.
- Abeni, B.A., Frank-Peterside, N., Agbagwa, O.E., Adewuyi, S.A., Cookey, T.I. & Okonko, I.O. (2020). Seropositivity of Hepatitis C Virus Among Intending Blood Donors in Rivers State, Nigeria. *Asian Journal of Research and Reports in Gastroenterology* 3(3): 24-31
- Abera B, Zenebe Y, Mulu W, Kibret M, Kahsu G. Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected children at the Felgehiwot referral hospital, Ethiopia. *BMC Research Notes*. 2014; 7:838. <https://doi.org/10.1186/1756-0500-7-838> PMID: 25421947
- Agboghoroma, C. O., & Ukaire, B. C. (2020). Prevalence and Risk Factors of Human Immunodeficiency Virus and Hepatitis C Virus Infection among Pregnant Women Attending Antenatal Care at a Tertiary Hospital in Abuja, Nigeria. *Nigerian Medical Journal: Journal of the Nigeria Medical Association*, 61(5), 245–251. https://doi.org/10.4103/nmj.NMJ_241_19
- Alter M. J. (2007). Epidemiology of hepatitis C virus infection. *World journal of gastroenterology*, 13(17), 2436–2441. <https://doi.org/10.3748/wjg.v13.i17.2436>
- Balew, M., Moges, F., Yismaw, G., & Unakal, C. (2014). Assessment of hepatitis B virus and hepatitis C virus infections and associated risk factors in HIV infected patients at Debretabor hospital, South Gondar, Northwest Ethiopia. *Asian Pacific Journal of Tropical Disease*, 4(1), 1–7. [https://doi.org/10.1016/S2222-1808\(14\)60304-2](https://doi.org/10.1016/S2222-1808(14)60304-2)
- Balogun, T. M., Emmanuel, S., & Ojerinde, E. F. (2012). HIV, Hepatitis B and C viruses' coinfection among patients in a Nigerian Tertiary Hospital. *Pan African Medical Journal*, 12, 100
- Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. *International Journal of Infectious Diseases*. 2010; 14(12): e1024–e31. <https://doi.org/10.1016/j.ijid.2010.06.013> PMID: 20870439
- Bartonova, V. G., Briggs, J. A. G., Riches, J. D., Glass, B., Zanetti, C. & Krausslich, H. G. (2009). Structure and assembly of immature HIV. *PNAS*; 106(27), 11090-11095.
- Baseke, J., Musenero, M., & Mayanja-Kizza, H. (2015). "Prevalence of hepatitis B and C and relationship to liver damage in HIV infected patients attending joint clinical research centre clinic, Kampala, Uganda," *African Health Science*; 15, 322-327.

- Belo, A. C. (2000). prevalence of hepatitis B virus markers in surgeons in Lagos, Nigeria. *East African Medical Journal*; 77: 283 -285
- BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutierrez-Valencia A, Ruiz-Valderas R, Viciano P, Lo'pez-Corte's LF. Higher Activation in CD4+ T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy. *AIDS research and human retroviruses*. 2016; 32(1):6–11. <https://doi.org/10.1089/AID.2014.0299> PMID: 26414169
- Benova, L., Mohamoud, Y. A., Calvert, C., & Abu-Raddad, L. J. (2014). Vertical transmission of hepatitis C virus: systematic review and meta-analysis. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 59(6), 765–773. <https://doi.org/10.1093/cid/ciu447>
- Boateng R, Mutocheluh M, Dompok A, Obiri-Yeboah D, Odame Anto E, Owusu M, et al. (2019). Sero-prevalence of Hepatitis B and C viral coinfections among HIV-1 infected ART-naïve individuals in Kumasi, Ghana. *PLoS ONE* 14(4): e0215377. <https://doi.org/10.1371/journal.pone.0215377>
- Buseri, F. I., Muhibi, M. A., & Jeremiah, Z. A. (2009). Sero-epidemiology of transfusion-transmissible infectious diseases among blood donors in Osogbo, south-west Nigeria. *Blood transfusion = Trasfusione del sangue*, 7(4), 293–299. <https://doi.org/10.2450/2009.0071-08>
- Chakraborty R, Rees G, Bourboulia D, Cross AM, Dixon JR, D'Agostino A, et al. Viral Coinfections among African Children Infected with Human Immunodeficiency Virus Type 1. *Clin Infect Dis*. 2003; 36 (7):922–4. <https://doi.org/10.1086/368207> PMID: 12652394
- Chen, X., He, J. M., Ding, L. S., Zhang, G. Q., Zou, X. B., & Zheng, J. (2013). Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China. *Archives of Virology*, 158(9), 1889–1894. <https://doi.org/10.1007/s00705-013-1681-z>
- Colpitts, C.C.; Tsai, P.-L.; Zeisel, MB Hepatitis C Virus Entry: An Intriguingly Complex and Highly Regulated Process. *Int. J. Mol. Sci.* **2020**, *21*, 2091. <https://doi.org/10.3390/ijms21062091>
- Cooke, G. S., Lemoine, M., Thursz, M., Gore, C., Swan, T., Kamarulzaman, A., DuCros, P., & Ford, N. (2013). Viral hepatitis and the Global Burden of Disease: a need to regroup. *Journal of viral hepatitis*, 20(9), 600–601. <https://doi.org/10.1111/jvh.12123>
- Cookey, T. I., Okonko, I. O. & Frank-Peterside, N. (2021). Zero Prevalence of HIV and HCV Coinfection in the Highly HIV-infected Population of Rivers State, Nigeria. *Asian Journal of Research in Medical and Pharmaceutical Sciences*, 10(3): 9-16
- Cooper CL, Mills E, Wabwire BO, Ford N, Olupot-Olupot P. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. *Int J Infect Dis*. 2009; 13(3):302–6. <https://doi.org/10.1016/j.ijid.2008.06.042> PMID: 19004656
- Deress, T., Million, Y., Belachew, T., Jemal, M., & Girma, M. (2021). Seroprevalence of Hepatitis C Viral Infection in Ethiopia: A Systematic Review and Meta-Analysis. *TheScientificWorldJournal*, 2021, 8873389. <https://doi.org/10.1155/2021/8873389>
- Diwe CK, Okwara EC, Enwere OO, Azike JE, Nwaimo NC (2013). Sero-prevalence of hepatitis B virus and hepatitis C virus among HIV patients in a suburban University Teaching Hospital in Southeast Nigeria. *Pan African Medical Journal*, 16:7
- Durowaye MO, Ernest SK, Ojuawo IA. Prevalence of HIV coinfection with Hepatitis B and C viruses among children at a tertiary hospital in Ilorin, Nigeria. *Int J Clin Med Res*. 2014; 1:42–7.
- Egah, D. Z., Mandong, B. M., Iya, D., Gomwalk, N. E., Audu, E. S., Banwat, E. B., & Onile, B. A. (2004). Hepatitis C virus antibodies among blood donors in Jos, Nigeria. *Annals of African Medicine*, 3(1), 35–37.

- Ejeliogu EU, Oguiche S, Ebonyi AO, Okpe SE, Yiltok ES, John CC, et al. Human immunodeficiency virus and Hepatitis C virus coinfection in children in Jos, Nigeria. *Opn Sci J Clin Med*. 2014; 2:69–72.
- Eke CB, Ogbodo SO, Ukoha OM, Ibekwe RC, Asinobi IN, Ikefuna AN, et al. Seroprevalence and Risk Factors of Hepatitis B Virus Infection among Adolescents in Enugu, Nigeria. *J Trop Pediatr*. 2015; 61 (6):407–13. <https://doi.org/10.1093/tropej/fmv035> PMID: 26411561
- Esan AJ, Omisakin CT, Ojo-Bola T, Owoseni MF, Fasakin KA, Ogunleye AA. Seroprevalence of Hepatitis B and Hepatitis C Virus Coinfection among Pregnant Women in Nigeria. *Am J Biomed Res*. 2014; 2 (1):11–5.
- Umumararungu, E., Ntaganda, F., Kagira, J., & Maina, N. (2017). Prevalence of hepatitis C virus infection and its risk factors among patients attending Rwanda Military Hospital, Rwanda. *BioMed research international*, 2017.
- Fox JM, Newton R, Bedaj M, Keding A, Molyneux E, Carpenter LM, et al. Prevalence of hepatitis C virus in mothers and their children in Malawi. *Trop Med Int Health*. 2015; 20(5):638–42. <https://doi.org/10.1111/tmi.12465> PMID: 25611121
- Gupta S, Sodhi SP, Brar GK, Bansal RN. Risk factors for hepatitis C: A clinical study. *J Med Sci* 2018; 38:215-221
- Hsu, J.-T.; Hsu, P.-I.; Shie, C.-B.; Chuah, S.-K.; Wu, I.-T.; Huang, W.-W.; Tang, S.-Y.; Tsai, K.-F.; Kuo, L.-F.; Ghose, S.; Hsu, J.-C.; Shih, C.-A. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. *Medicina* **2022**, *58*, 436. <https://doi.org/10.3390/medicina58030436>
- Ikeako, L., Ezegwui, H., Ajah, L., Dim, C., & Okeke, T. (2014). Seroprevalence of Human Immunodeficiency Virus, Hepatitis B, Hepatitis C, Syphilis, and Coinfections among Antenatal Women in a Tertiary Institution in South East, Nigeria. *Annals of Medical and Health Sciences Research*, 4(6), 954–958. <https://doi.org/10.4103/2141-9248.144925>
- Ikpeme, E.E., Etukudo, O.M. & Ekrikpo, U.E. (2013). Seroprevalence of HBV and HIV coinfection in children and outcomes following highly active antiretroviral therapy (HAART) in Uyo, South-South Nigeria. *Africa Health Science*. 13(4):955–61.
- Ionita, G., Malviya, A., Rajbhandari, R., Schluter, W. W., Sharma, G., Kakchapati, S., Rijal, S., & Dixit, S. (2017). Seroprevalence of hepatitis B virus and hepatitis C virus coinfection among people living with HIV/AIDS visiting antiretroviral therapy centres in Nepal: a first nationally representative study. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases*, 60, 64–69. <https://doi.org/10.1016/j.ijid.2017.04.011>
- Isa MA, Kolo BS, Ibrahim A, Bulakarima A, Dawud H. Prevalence of Hepatitis C Virus among Children Attending University of Maiduguri Teaching Hospital, Nigeria. *Int J Sci Res Methodol*. 2015; 2(2):14–21.
- Jemilohun, A. C., Oyelade, B. O., & Oiwoh, S. O. (2014). Prevalence of Hepatitis C virus antibody among undergraduates in Ogbomoso, Southwestern Nigeria. *African Journal of infectious Diseases*, 8(2), 40-43.
- Kassim OD, Oyekale TO, Aneke JC, Durosini MA. Prevalence of seropositive blood donors for hepatitis B, C and HIV viruses at the Federal Medical Centre, Ado-Ekiti Nigeria. *Ann Trop Pathol*. 2012; 3:47–55.
- Khaderi S, Shepherd R, Goss JA, Leung DH. Hepatitis C in the pediatric population: Transmission, natural history, treatment and liver transplantation. *World J Gastroenterol*. 2014; 20(32):11281–6. <https://doi.org/10.3748/wjg.v20.i32.11281>
- Konopricki D, Mocroft A, & deWit S. (2005). Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. *AIDS*; 19:593-601.

- Lawal, M. A., Adeniyi, O. F., Akintan, P. E., Salako, A. O., Omotosho, O. S., & Temiye, E. O. (2020). Prevalence of and risk factors for hepatitis B and C viral coinfections in HIV infected children in Lagos, Nigeria. *PLoS one*, 15(12), e0243656. <https://doi.org/10.1371/journal.pone.0243656>
- Lee, K. K., Stelzle, D., Bing, R., Anwar, M., Strachan, F., Bashir, S., Newby, D. E., Shah, J. S., Chung, M. H., Bloomfield, G. S., Longenecker, C. T., Bagchi, S., Kottlilil, S., Blach, S., Razavi, H., Mills, P. R., Mills, N. L., McAllister, D. A., & Shah, A. S. V. (2019). Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. *The Lancet. Gastroenterology & hepatology*, 4(10), 794–804. [https://doi.org/10.1016/S2468-1253\(19\)30227-4](https://doi.org/10.1016/S2468-1253(19)30227-4)
- Lemoine M, Eholie' S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach. *J Hepatol*. 2015; 62(2):469–76. <https://doi.org/10.1016/j.jhep.2014.10.008> PMID: 25457207
- Lesi O. A, Kehinde M. O, Oguh D. N, & Amira C. O. (2007). Hepatitis B and C virus infection in Nigerian patients with HIV/AIDS. *Niger Postgraduate Medical journal*.; 14(2): 129-33
- Lodenyo, H., Schoub, B., Ally, R., Kairu, S., & Segal, I. (2000). Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. *East African Medical Journal*, 77(1), 13–15. <https://doi.org/10.4314/eamj.v77i1.46369>
- Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013). Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology (Baltimore, Md.)*, 57(4), 1333–1342. <https://doi.org/10.1002/hep.26141>
- Muriuki BM, Gicheru MM, Wachira D, Nyamache AK, Khamadi SA. Prevalence of hepatitis B and C viral coinfections among HIV-1 infected individuals in Nairobi, Kenya. *BMC Research Notes*. 2013; 6 (1):363. <https://doi.org/10.1186/1756-0500-6-363> PMID: 24016453
- Nel E, Sokol RJ, Comparcola D, Nobili V, Hardikar W, Gana JC, et al. Viral Hepatitis in Children. *J Pediatr Gastroenterol Nutr*. 2012; 55(5):500–505. <https://doi.org/10.1097/MPG.0b013e318272aee7> PMID: 22983372
- Nwolisa, E., Mbanefo, F., Ezeogu, J. & Amadi, P. (2013). Prevalence of Hepatitis B coinfection amongst HIV infected children attending a care and treatment centre in Owerri, South-eastern Nigeria. *Pan African Medical Journal*. 14:89.
- O'Leary M, Bagg J, Welbury R, Hutchinson SJ, Hague R, Geary I, et al. The seroprevalence of hepatitis C virus infection among children and their mothers attending for dental care in Glasgow, Scotland, United Kingdom. *J Infect Public Health*. 2017; 10(4):470–8. <https://doi.org/10.1016/j.jiph.2016.08.001> PMID: 27568000
- Odjimogho, S., Agofure, O., Okandeji-Barry, O. R. A., & Ibrahim, Z. L. (2018). Prevalence of hepatitis B and C among HIV/AIDS patients attending Bingham University Teaching Hospital Jos Plateau State Nigeria: A retrospective study. *Journal of Public Health and Epidemiology*, 10(6), 198-204
- Ogbodo, E. N., Otue A. & Okonko, I. O. (2015). Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria. *African Health Sciences* 15(3):728-736
- Ogboghodo BC, Aigbirior MA, Bazuaye GN, Ebomoyi MI, Iyawe VI. Hepatitis C Virus and Human Immunodeficiency Virus-I (HIV) Coinfection in Children in Benin City, Nigeria. *Afr J Biomed Res*. 2009; 12(1):1–6.

- Ogundele OA, Olorunsola A, Bakare B, Adegoke IA, Ogundele T, Fehintola FO, et al. Sero-prevalence and knowledge of hepatitis of hepatitis B and C among health workers in a specialist hospital setting. *Eur J Prev Med* 2017;5:7-12
- Ogwu-Richard S.A, Ojo DA, Akingbade OA, & Okonko IO. (2015). Triple Positivity of HBsAg, Anti-HCV antibody, and HIV and their influence on CD4⁺ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria. *African Health Sciences* 15(3):719-727
- Okocha EC, Aneke JC, Ezeh TU, Ibeh NC, Nwosu GA, Okorie IO, et al. The epidemiology of transfusion-transmissible infections among blood donors in Nnewi, southeast Nigeria. *Afr J Med Health Sci.* 2015;14:125–129. doi: 10.4103/2384-5589.170183
- Okonko, I. O., Cookey, T. I. & Stanley, C. N. (2020a). Detection of HIV 1 & 2 Antibodies Among Patients Patronizing Some Private Laboratories in Rivers State, Nigeria. *Singapore Journal of Scientific Research*, 10:88-93
- Okonko, I. O., Nwoke, C. M., Cookey, T. I., & Stanley, C. N. (2020b). Prevalence of HIV among Patients Patronizing a Private Laboratory in Port Harcourt Metropolis, Nigeria. *International Journal of Virology & Molecular Biology*, 9(1): 1-5
- Okonko IO, Cookey TI & Innocent-Adiele HC. (2022). Dual positivity of HIV and anti-HCV in the highly infected population of Rivers State, Nigeria. *International Journal of Scientific Research Updates*, 04(02), 039–048
- Okonko IO, Oyediji TO, Anugweje KC, Adeniji FO, Alli JA, Abraham OA. Detection of HCV antibody among intending blood donors. *Nature and Science*. 2012;10(1): 53-58
- Okonko, I. & Ernest Nwagwu, H. (2023). Serological Prevalence of Hepatitis C Virus among Febrile Patients Attending a General Hospital in Emohua LGA, Rivers State, Nigeria. *Preprints* 2023, 2023030094. <https://doi.org/10.20944/preprints202303.0094.v1>.
- Okonko, I. O., Ikunga, C. V., Anugweje, K. C. & Okerentugba, P. O. (2014). Anti-hepatitis C virus (HCV) antibody detection among fresh undergraduate students in Port Harcourt, Nigeria. *Basic Sciences of Medicine*, 3(2): 26–29.
- Okoroiwu HU, Okafor IM, Asemota EA, Okpokam DC. Seroprevalence of transfusion-transmissible infections (HBV, HCV, syphilis and HIV) among prospective blood donors in a tertiary health care facility in Calabar, Nigeria; An eleven years evaluation. *BMC Public Health*. 2018;18: 645.
- Olufemi, A., Emmanuel, A., Zaccheus, A., Ibrahim, W., Funmilayo, E., & Patience, A. (2009). Hepatitis B and C virus coinfection in Nigerian patients with HIV infection. *Journal of Infectious Diseases* 3(5):369–375.
- Oluremi AS, Opaleye OO, Ogbolu DO, Alli OAT, Ashiru FT, Alaka OO, et al. Serological evidence of HIV, Hepatitis B, C, and E viruses among liver disease patients attending tertiary hospitals in Osun State, Nigeria. *Journal of Immunoassay and Immunochemistry*. 2021;42(1): 69-81.
- Omatola, C. A., Idofe, J., Okolo, M. O., Adejo, P. O., Maina, M. M., & Oyiguh, J. A. (2019). Seroprevalence of HBV among people living with HIV in Anyigba, Kogi State, Nigeria. *African Health Sciences*, 19(2), 1938–1946. <https://doi.org/10.4314/ahs.v19i2.17>
- Omolade O & Adeyemi A. Prevalence of hepatitis C virus antibody among university students in Nigeria. *J Virus Erad* 2018;4:228-9
- Oni AO, Harrison TJ. Genotypes of hepatitis C virus in Nigeria. *J Med Virol.* 1996; 49(3):178–86. [https://doi.org/10.1002/\(SICI\)1096-9071\(199607\)49:3<178::AID-JMV4>3.0.CO;2-1](https://doi.org/10.1002/(SICI)1096-9071(199607)49:3<178::AID-JMV4>3.0.CO;2-1) PMID: 8818962
- Onyekwere, C. A., & Hameed, L. (2015). Hepatitis B and C virus prevalence and association with demographics: report of population screening in Nigeria. *Tropical doctor*, 45(4), 231–235. <https://doi.org/10.1177/0049475514560211>

- Onyekwere, C. A., O Ogbera, A., Olusola Dada, A., O Adeleye, O., O Dosunmu, A., Akinbami, A. A., Osikomaiya, B., & Hameed, O. (2016). Hepatitis C Virus (HCV) Prevalence in Special Populations and Associated Risk Factors: A Report From a Tertiary Hospital. *Hepatitis monthly*, 16(5), e35532. <https://doi.org/10.5812/hepatmon.35532>
- Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and adolescents. *J Hepatol.* 2012; 57(4):885–96. <https://doi.org/10.1016/j.jhep.2012.03.036> PMID: 22634122
- Patnaik, R. & Tsai, E. (2022). Hepatitis C Virus Treatment and Solid Organ Transplantation. *Gastroenterology & Hepatology*, 18(2): 85-94
- Polaris Observatory HCV Collaborators. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015, a modelling study. *Lancet Gastroenterol. Hepatol.*, 2, 161–176
- Puoti M, Manno D, Nasta P, Carosi G. Hepatitis B Virus and HIV Coinfection in Low-Income Countries: Unmet Needs I; 46(3):367–9. <https://doi.org/10.1086/525532> PMID: 18171305
- Rao V.B., Johari N., du Cros P., Messina J., Ford N., Cooke G. S., Hepatitis C Seroprevalence and HIV coinfection in Sub Saharan Africa: a systematic review and meta-analysis. *Lancet Infect Dis.* 2015 JUL;19(7):819–824.
- Riou J, Aït Ahmed M., Blake A, Vozlinsky S, Brichler S, Eholié S, Boëlle PY, Fontanet A. HCV epidemiology in Africa group hepatitis C virus seroprevalence in adults in Africa: A systematic review and meta-analysis. *Journal of Viral Hepatitis*, 2016;23:244–255.
- Rouet, F., Chaix, M. L., Inwoley, A., Anaky, M. F., Fassinou, P., Kpozehouen, A., Rouzioux, C., Blanche, S., Msellati, P., & Programme Enfant Yopougon (Agence Nationale de Recherches sur le SIDA et les Hépatites Virales B et C 1244/1278) (2008). Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. *Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America*, 46(3), 361–366. <https://doi.org/10.1086/525531>
- Sadoh AE, Sadoh WE, Iduoriyekemwen NJ. HIV coinfection with hepatitis B and C viruses among Nigerian children in an antiretroviral treatment programme. *South Afr J Child Health.* 2011; 5(1):7–10.
- Schuval S, Van Dyke RB, Lindsey JC, Palumbo P, Mofenson LM, Oleske JM, et al. Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. *Arch Pediatr Adolesc Med.* 2004; 158(10):1007–13. <https://doi.org/10.1001/archpedi.158.10.1007> PMID: 15466691
- Sulkowski, M. S. D. and Thomas, D. L. M. D. (2003). Hepatitis C virus in the HIV- Infected Person [Review]. *Annals of Internal Medicine*, 138:197-207
- Telatela, S. P., Matee, M. I., & Munubhi, E. K. (2007). Seroprevalence of hepatitis B and C viral coinfections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. *BMC public health*, 7: 338. <https://doi.org/10.1186/1471-2458-7-338>
- Tessema, B., Yismaw, G., Kassu, A., Amsalu, A., Mulu, A., Emmrich, F., & Sack, U. (2010). Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years. *BMC infectious diseases*, 10, 111. <https://doi.org/10.1186/1471-2334-10-111>
- Thomas D L, Astemborski J, Rai R M, Anania F A, Schaeffer M, Galai N, Nolt K, Nelson K E, Strathdee S A, Johnson L, Laeyendecker O, Boitnott J, Wilson L E, Vlahov D.

- (2000). The natural history of hepatitis C virus infection: host, viral, and environmental factors. *JAMA*, 284:450–456.
- Tsai, M. S., Hsu, Y. C., Yu, P. C., Lin, C. L., & Kao, C. H. (2015). Long-term risk of acute coronary syndrome in hepatitis C virus-infected patients without antiviral treatment: A cohort study from an endemic area. *International journal of cardiology*, 181, 27–29. <https://doi.org/10.1016/j.ijcard.2014.11.200>
- Tsai W-L, Wang C-F, Cheng J-S, Chen W-C, Bair M-J, Lo C-C (2020). Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real-world experience. *PLoS ONE* 15(1): e0227424. <https://doi.org/10.1371/journal.pone.0227424>
- Tsai, P. C., Huang, C. I., Yeh, M. L., Huang, C. F., Hsieh, M. H., Yang, J. F., Hsu, P. Y., Liang, P. C., Lin, Y. H., Jang, T. Y., Hsieh, M. Y., Dai, C. Y., Lin, Z. Y., Chen, S. C., Huang, J. F., Yu, M. L., Chuang, W. L., & Chang, W. Y. (2021). Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. *BMJ open*, 11(3), e042861. <https://doi.org/10.1136/bmjopen-2020-042861>
- Udeze, A. O., Bamidele, R. A., Okonko, I. O., and Sule, W. F. (2011). Hepatitis C Virus (HCV) Antibody Detection Among First Year Students of University of Ilorin, Ilorin, Nigeria. *World J of Med Sci*. 6:162-167.
- Udeze, A. O., Okonko, I. O., Donbraye, E., Sule, W. F., Fadeyi, A. and Uche, L. N. (2009). Seroprevalence of Hepatitis C Virus Antibodies Amongst Blood Donors in Ibadan, Southwestern Nigeria. *World ApplSci J.*, 7: 1023-1028.
- Villano S A, Vlahov D, Nelson K E, Cohn S, Thomas D L. (1999). Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. *Hepatology*, 29:908–914.
- World Health Organization (WHO, 2023a). Global HIV Programme: HIV data and statistics. <https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics>. Published 9 November 2022. Accessed 8 March 2023
- World Health Organization (WHO, 2023b). HIV Key Facts. <https://www.who.int/news-room/fact-sheets/detail/hiv-aids>. Published 9 November 2022. Accessed 8 March 2023
- World Health Organization (WHO, 2017). Global hepatitis report, 2017. Available from: <http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/>. Published 9 November 2022. Accessed 8 March 2023
- World Health Organization (WHO, 2023c). HCV Key Facts. <https://www.who.int/news-room/fact-sheets/detail/hiv-aids>. Published 24 June 2022. Accessed 8 March 2023
- World Health Organization (WHO, 2020). Hepatitis C; 2020. Available from: <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>. Published 9 November 2022. [Last accessed on 2020 3 May]
- Yu, M-L, Tsai, W-L, Chu, C-J, Kao, J-H. Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study. *Kaohsiung J Med Sci*. 2021; 37: 245– 252. <https://doi.org/10.1002/kjm2.12317>
- Zhou, S., Zhao, Y., He, Y., Li, H., Bulterys, M., Sun, X., Dou, Z., Robinson, M., & Zhang, F. (2010). Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009. *Journal of acquired immune deficiency syndromes (1999)*, 54(2), 191–196. <https://doi.org/10.1097/QAI.0b013e3181c99226>